Sodium nitrite-based drug moves to Phase IIa trial
MedCity News reports that a drug developed by Cleveland-based company TheraVasc has moved into the next stage of testing to determine its effects on peripheral artery disease (PAD).
Individuals who buy Lipitor or Plavix at U.S. or Canadian online pharmacies may be interested in news of a medication currently in Phase IIa trials. MedCity News reports that a drug developed by Cleveland-based company TheraVasc has moved into the next stage of testing to determine its effects on peripheral artery disease (PAD).
The medication, which is being tested by the Centers for Disease Control and Prevention, is a variant of sodium nitrite, the news source said.
This compound is a vasodilator, meaning that an injected solution of the substance causes blood vessels to widen, allowing freer blood flow. TheraVasc's special preparation of sodium nitrite will be, if approved, the first version of the drug in pill form.
PAD is characterized by the buildup of plaque in the arteries of the body's extremities, primarily in the legs. Over time, the gradual blockage of the blood vessels in the legs or feet can lead to tingling, numbness, difficulty fighting infection and - in extreme cases - gangrene and eventual amputation.
One in three individuals with coronary heart disease develop PAD, according to the National Heart Lung and Blood Institute.
|
my account
